Safety and Efficacy of Efgartigimod for Generalized Myasthenia Gravis: A Systematic Review and Meta-Analysis.
Efgartigimod shows short-term benefits in improving symptoms of generalized myasthenia gravis, but these benefits may not last over time.
Where it sits
this study against the rest of the efpeglenatide corpusSummary and findings
This systematic review and meta-analysis evaluated the efficacy and safety of efgartigimod in patients with generalized myasthenia gravis (gMG). The analysis included 11 studies with a total of 480 participants, focusing on outcomes such as MG-ADL and QMG scores. Efgartigimod showed improvement in these scores at peak effect but not at the end of follow-up.
Abstract
<h4>Background</h4>Severe muscle weakness is a hallmark of generalized myasthenia gravis (gMG), a chronic autoimmune disease that severely reduces quality of life. Traditional immunosuppressive treatments can have significant adverse effects and only partially relieve symptoms. Clinical trials have demonstrated the potential of efgartigimod, a neonatal Fc receptor (FcRn) antagonist that lowers harmful IgG autoantibodies. This systematic review and meta-analysis assessed its efficacy and safety, analyzing randomized controlled evidence separately from uncontrolled real-world evidence.<h4>Methods</h4>Up until August 2025, we conducted a thorough search of PubMed, Scopus, and Web of Science, supplemented by the Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov, for observational studies and randomized controlled trials (RCTs) evaluating efgartigimod in gMG. Improvement in myasthenia gravis activities of daily living (MG-ADL), responder rates, adverse events, and quantitative myasthenia gravis (QMG) scores were the main outcomes. Placebo-controlled RCTs were pooled in two-arm meta-analyses (primary evidence) and uncontrolled cohort studies and case series in single-arm meta-analyses (supportive evidence), using random-effects models in Review Manager 5.4 and R (v4.4.2). Sensitivity, leave-one-out influence, and subgroup analyses were performed, 95% prediction intervals were calculated for single-arm outcomes, and the certainty of evidence was rated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. The review was retrospectively registered in PROSPERO (CRD420261518373).<h4>Results</h4>We included 11 studies (two RCTs, six cohort studies, and three case series) comprising 480 participants (385 efgartigimod-treated and 95 placebo-treated). In the RCTs, efgartigimod improved MG-ADL (mean differences [MD] = -2.62, 95% CI: -3.99 to -1.25, p = 0.0002) and QMG scores (MD = -4.59, 95% CI: -6.24 to -2.94, p < 0.00001) at peak effect, but the differences were not significant at the end of follow-up. MG-ADL responders were more frequent with efgartigimod than with placebo (risk ratios [RR] = 1.90, 95% CI: 1.40-2.56, p < 0.0001), including among acetylcholine receptor (AChR)-Ab+ patients (RR = 2.37, 95% CI: 1.61-3.47, p < 0.0001). The incidence of adverse events did not differ from placebo (RR = 0.93, 95% CI: 0.81-1.07, p = 0.29). Certainty of evidence was moderate for peak-effect, responder, and safety outcomes. In uncontrolled real-world studies, responses were observed in AChR-Ab+ and muscle-specific tyrosine kinase (MuSK)-Ab+ patients (MuSK-Ab+ pooled proportion = 0.781, 95% CI: 0.499-0.927; 18 patients) and corticosteroid doses decreased, but this evidence was of very low certainty. Single-arm estimates showed substantial to considerable heterogeneity (I<sup>2</sup> up to 98.8%) and wide 95% prediction intervals, although every contributing study showed improvement in MG-ADL and a reduction in corticosteroid dose. Randomized estimates were unchanged when restricted to the phase 3 ADAPT trial, which contributed 71%-92% of the statistical weight.<h4>Conclusion</h4>In randomized trials, efgartigimod produces clinically meaningful short-term improvement in gMG with an adverse event incidence comparable to placebo. Because the benefit was not maintained at the end of follow-up, cyclical, individualized retreatment is likely required. Real-world data suggest benefit across serological subtypes and a corticosteroid-sparing effect; however, these uncontrolled estimates were heterogeneous and of very low certainty, and larger, longer term controlled studies, ideally conducted independently of the manufacturer, are needed to confirm these findings.
Background
This paper addresses the efficacy and safety of efgartigimod for generalized myasthenia gravis (gMG), a condition characterized by severe muscle weakness. Prior treatments have significant adverse effects and only partially alleviate symptoms. The study is significant as it evaluates a novel FcRn antagonist that targets harmful IgG autoantibodies, potentially offering a new therapeutic approach.
Methods
The study involved a systematic review and meta-analysis of randomized controlled trials (RCTs) and observational studies assessing efgartigimod in gMG. A total of 11 studies were included, comprising 480 participants (385 treated with efgartigimod and 95 with placebo). The primary outcomes were improvements in MG-ADL and QMG scores, with analyses conducted using random-effects models.
Results
Efgartigimod demonstrated a significant improvement in MG-ADL with an MD of -2.62 (95% CI: -3.99 to -1.25, p = 0.0002) and in QMG scores with an MD of -4.59 (95% CI: -6.24 to -2.94, p < 0.00001) at peak effect. However, these differences were not maintained at the end of follow-up. The responder rate for MG-ADL was significantly higher in the efgartigimod group with an RR of 1.90 (95% CI: 1.40-2.56, p < 0.0001). The incidence of adverse events was comparable to placebo (RR = 0.93, 95% CI: 0.81-1.07, p = 0.29).
Interpretation
The findings suggest that efgartigimod can lead to short-term improvements in gMG, but the lack of sustained benefit at follow-up raises questions about long-term efficacy. While the statistical significance of the results is clear, the clinical significance may be limited by the short duration of follow-up and the need for cyclical retreatment. The study's reliance on uncontrolled data for some outcomes introduces additional uncertainty.
Key findings
- MD = -2.62, 95% CI: -3.99 to -1.25, p = 0.0002 for MG-ADL improvement.
- MD = -4.59, 95% CI: -6.24 to -2.94, p < 0.00001 for QMG score improvement.
- RR = 1.90, 95% CI: 1.40-2.56, p < 0.0001 for MG-ADL responders.
- RR = 0.93, 95% CI: 0.81-1.07, p = 0.29 for adverse events incidence.
- MuSK-Ab+ pooled proportion = 0.781, 95% CI: 0.499-0.927; 18 patients.
Limitations
- Moderate certainty of evidence for primary outcomes.
- Follow-up duration insufficient to assess long-term efficacy.
- Uncontrolled real-world data of very low certainty.
- Substantial heterogeneity in single-arm estimates (I² up to 98.8%).
- Small sample size in some studies.